UK Approves New Oral Cancer Drug for Blood Cancer Patients

Patients with two aggressive blood cancers just gained access to treatments that could add years to their lives without the burden of traditional chemotherapy.

The National Institute of Health and Care Excellence (NICE) approved two new drug combinations last week for adults in England and Wales diagnosed with chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). Both are challenging blood cancers that primarily affect older adults.

The most groundbreaking approval brings the first all-oral treatment regimen for CLL patients who haven't received prior therapy. The combination of acalabrutinib plus venetoclax reduced disease progression and death by 35% compared to standard chemotherapy. After three years, 77% of patients remained progression-free, compared to just 67% on traditional treatment.

For patients with mantle cell lymphoma, acalabrutinib combined with two other drugs extended the time before disease progression to 66.4 months. That's nearly 17 months longer than the 49.6 months seen with standard treatment.

These medications work differently than traditional chemotherapy. They block a specific enzyme called Bruton's tyrosine kinase that drives abnormal white blood cells to multiply. By shutting down this pathway, the drugs stop cancer cells from growing without attacking healthy cells the way chemotherapy does.

Dr. Toby Eyre, a haematologist at Oxford University Hospitals NHS Foundation Trust, highlighted another crucial benefit. "This fixed-duration treatment option provides eligible patients with access to an innovative regimen that offers the flexibility of planned time off treatment," he said. Patients can eventually stop taking the drugs rather than staying on medication indefinitely.

The Ripple Effect

The approval marks a shift in how blood cancers are treated across the UK's National Health Service. Thousands of newly diagnosed patients each year will now have access to targeted therapies that were once reserved for later-stage treatment.

Dr. David Lewis from Plymouth Hospitals NHS Trust emphasized the importance for mantle cell lymphoma patients specifically. "As an incurable disease that mainly affects older people, optimising treatment from the outset is critical," he explained. The approval could establish a new standard of care for patients who aren't eligible for transplants.

The treatments also reduce the physical burden on patients. An all-oral regimen means no hospital visits for infusions and potentially fewer severe side effects than traditional chemotherapy.

These approvals represent genuine progress in personalised medicine, giving doctors and patients more powerful tools to fight blood cancers while maintaining quality of life.